We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$308M
AUM Growth
-$38.9M
Cap. Flow
-$25.7M
Cap. Flow %
-8.35%
Top 10 Hldgs %
52.97%
Holding
98
New
10
Increased
19
Reduced
20
Closed
18

Top Buys

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$4.11M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$4M
3
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$2.94M
4
ETNB
89bio
ETNB
+$2.85M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.16M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$11.3M
2
KURA icon
Kura Oncology
KURA
+$5.64M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$3.92M
4
CGEN icon
Compugen
CGEN
+$3.73M
5
AKBA icon
Akebia Therapeutics
AKBA
+$3.69M

Sector Composition

Rank Sector Weight
1 Healthcare 96.07%
2 Miscellaneous 3.93%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STXS icon
1
Stereotaxis
STXS
$145M
$49M 15.92%
13,680,554
– –
IMMU
2
DELISTED
Immunomedics Inc
IMMU
$22.2M 7.21%
260,905
+10,000
+4% +$506K
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$21.6M 7.02%
233,089
+5,000
+2% +$385K
FATE icon
4
Fate Therapeutics
FATE
$291M
$17.5M 5.7%
438,460
-52,401
-11% -$1.83M
ARCT icon
5
Arcturus Therapeutics
ARCT
$432M
$9.85M 3.2%
229,652
+80,635
+54% +$4M
SAGE
6
DELISTED
Sage Therapeutics
SAGE
$9.68M 3.15%
158,306
-7,000
-4% -$355K
DXCM icon
7
DexCom
DXCM
$34.3B
$8.71M 2.83%
84,552
– –
NBIX icon
8
Neurocrine Biosciences
NBIX
$15.7B
$8.67M 2.82%
90,208
+17,000
+23% +$1.97M
DRNA
9
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$8.17M 2.66%
454,236
– –
IBB icon
10
iShares Biotechnology ETF
IBB
$10.5B
$7.57M 2.46%
55,900
+1,000
+2% +$136K
LKFT
11
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$6.3M 2.05%
44,375
– –
CSII
12
DELISTED
Cardiovascular Systems, Inc.
CSII
$5.95M 1.93%
151,200
– –
PRQR icon
13
ProQR Therapeutics
PRQR
$323M
$5.93M 1.93%
1,237,400
– –
ARNA
14
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.67M 1.84%
75,815
-169,327
-69% -$11.3M
BHVN
15
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$5.5M 1.79%
84,600
-3,000
-3% -$197K
AGTC
16
DELISTED
Applied Genetic Technologies Corporation
AGTC
$5.32M 1.73%
1,095,139
-65,739
-6% -$359K
ATRC icon
17
AtriCure
ATRC
$2.47B
$5.32M 1.73%
133,229
– –
ASND icon
18
Ascendis Pharma A/S
ASND
$16.3B
$4.51M 1.47%
29,237
+15,000
+105% +$2.16M
IDYA icon
19
IDEAYA Biosciences
IDYA
$3.87B
$4.17M 1.35%
+331,661
New +$4.11M
LMNX
20
DELISTED
Luminex Corp
LMNX
$4.04M 1.31%
154,091
– –
XENE icon
21
Xenon Pharmaceuticals
XENE
$5.81B
$3.84M 1.25%
346,535
– –
CNST
22
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$3.67M 1.19%
180,942
+10,000
+6% +$244K
AERI
23
DELISTED
Aerie Pharmaceuticals
AERI
$3.35M 1.09%
284,440
+5,000
+2% +$60.9K
TVRD
24
Tvardi Therapeutics
TVRD
$24.3M
$3.15M 1.02%
6,872
-3,434
-33% -$1.99M
AFMD
25
DELISTED
Affimed
AFMD
$3.13M 1.02%
92,428
+7,928
+9% +$300K
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, DAFNA Capital Management held 98 positions worth $308M, down 11% from $347M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management withdrew a net $25.7M in Q3 2020, closing 18 positions and reducing 20 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $2.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, DAFNA Capital Management opened a new position in IDEAYA Biosciences worth $4.17M.

  • DAFNA Capital Management's largest Q3 2020 buy was IDEAYA Biosciences: 331,661 shares worth $4.17M.
  • DAFNA Capital Management added most to Arcturus Therapeutics in Q3 2020, an estimated $4M increase.
  • DAFNA Capital Management's biggest Q3 2020 reduction was Arena Pharmaceuticals Inc, cutting an estimated $11.3M.
  • DAFNA Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q3 2020, selling an estimated $2.5M.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $308M portfolio in Q3 2020.
  • DAFNA Capital Management opened 10 new positions and closed 18 in Q3 2020.
  • DAFNA Capital Management's portfolio value fell 11% quarter-over-quarter to $308M.

Based on DAFNA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.